Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Jaguar Health (JAGX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Jaguar Health (JAGX) over the last 11 years, with Q3 2025 value amounting to 234.77%.

  • Jaguar Health's EBITDA Margin fell 11200.0% to 234.77% in Q3 2025 from the same period last year, while for Sep 2025 it was 278.52%, marking a year-over-year increase of 99500.0%. This contributed to the annual value of 263.76% for FY2024, which is 875500.0% up from last year.
  • As of Q3 2025, Jaguar Health's EBITDA Margin stood at 234.77%, which was down 11200.0% from 268.78% recorded in Q2 2025.
  • Jaguar Health's 5-year EBITDA Margin high stood at 192.82% for Q4 2022, and its period low was 3007.79% during Q2 2021.
  • Moreover, its 5-year median value for EBITDA Margin was 314.16% (2022), whereas its average is 546.08%.
  • In the last 5 years, Jaguar Health's EBITDA Margin crashed by -27409500bps in 2021 and then skyrocketed by 27859800bps in 2022.
  • Over the past 5 years, Jaguar Health's EBITDA Margin (Quarter) stood at 520.29% in 2021, then skyrocketed by 63bps to 192.82% in 2022, then tumbled by -70bps to 328.57% in 2023, then grew by 29bps to 232.46% in 2024, then fell by -1bps to 234.77% in 2025.
  • Its last three reported values are 234.77% in Q3 2025, 268.78% for Q2 2025, and 425.52% during Q1 2025.